ABBOTT LABORATORIES Form 10-Q August 06, 2013

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q								
(Mark One)								
x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934								
For the quarterly period ended June 30, 2013								
OR								
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934								

For the transition period from

to

Commission File No. 1-2189

ABBOTT LABORATORIES

An Illinois Corporation

I.R.S. Employer Identification No. 36-0698440

100 Abbott Park Road

Abbott Park, Illinois 60064-6400

Telephone: (847) 937-6100

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):

Large Accelerated Filer x Accelerated Filer o

Non-Accelerated Filer o Smaller reporting company o

(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

As of June 30, 2013, Abbott Laboratories had 1,554,125,355 common shares without par value outstanding.

PART I. FINANCIAL INFORMATION

Abbott Laboratories and Subsidiaries

Condensed Consolidated Financial Statements

(Unaudited)

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Earnings

(Unaudited)

(dollars and shares in thousands except per share data)

	Three Months Ended June 30				Six Months Ended June 30		
	2013		2012		2013		2012
Net Sales	\$ 5,446,025	\$	5,313,297	\$	10,823,920	\$	10,596,982
Cost of products sold	2,544,825		2,370,056		4,976,628		4,729,220
Amortization of intangible assets	196,892		194,823		396,314		404,413
Research and development	362,557		370,605		708,880		734,319
Selling, general and administrative	1,714,275		1,813,623		3,499,834		3,655,655
Total Operating Cost and Expenses	4,818,549		4,749,107		9,581,656		9,523,607
Operating Earnings	627,476		564,190		1,242,264		1,073,375
Interest expense	40,526		83,288		81,283		165,368
Interest (income)	(16,901)		(18,889)		(31,951)		(35,155)
Net foreign exchange loss (gain)	10,748		(24,536)		39,613		(9,630)
Other (income) expense, net	(7,646)		(5,177)		(1,981)		(40,088)
Earnings from Continuing Operations Before							
Taxes	600,749		529,504		1,155,300		992,880
Taxes on Earnings from Continuing							
Operations	124,694		118,663		134,584		230,824
Earnings from Continuing Operations	476,055		410,841		1,020,716		762,056
Earnings from Discontinued Operations, net							
of taxes			1,313,771				2,204,680
Net Earnings	\$ 476,055	\$	1,724,612	\$	1,020,716	\$	2,966,736
Basic Earnings Per Common Share							
Continuing Operations	\$ 0.30	\$	0.26	\$	0.65	\$	0.48
Discontinued Operations			0.83				1.39
Net Earnings	\$ 0.30	\$	1.09	\$	0.65	\$	1.87
Diluted Earnings Per Common Share							
Continuing Operations	\$ 0.30	\$	0.26	\$	0.64	\$	0.47
Discontinued Operations			0.82				1.38
Net Earnings	\$ 0.30	\$	1.08	\$	0.64	\$	1.85
Cash Dividends Declared Per Common Share	\$ 0.14	\$	0.51	\$	0.28	\$	1.02
Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share	1,560,519		1,572,099		1,564,894		1,572,681

Dilutive Common Stock Options and Awards 16,165 16,403 16,726 15,996